

Member Name: _____ DOB: _____

Member ID (UMI): _____ Medicare Commercial

Address: _____

ORDERING/ATTENDING PROVIDER

Physician Name: _____ NPI: _____

Address: _____

Office Contact: _____ Phone Number: _____ Fax Number: _____

SITE OF CARE

Place of Service (please select one)

Home Infusion Office – Professional Ambulatory Infusion Suite – Professional Outpatient Hospital

Is the site of care affiliated with a hospital or will the claim be billed as a facility claim? Yes No

Place of Service Name: _____ NPI: _____ Tax ID: _____

Address: _____

Phone Number: _____ Fax Number: _____

Drug Supplier (please select one)

Supplied by a Specialty Pharmacy (for Home Infusion, Office – Professional, or Ambulatory Infusion Suite – Professional)

Pharmacy Name: _____ Pharmacy NPI: _____

Buy & Bill (for Office – Professional or Outpatient Hospital administration)

DRUG INFORMATION

Drug Name: **ENTYVIO (J3380)** Strength or Dose: _____ Date(s) of service: _____

Directions: _____ Quantity (# of doses/visits): _____

CLINICAL INFORMATION

Diagnosis code (ICD10): _____ **Diagnosis Description below (please check one)**

<input type="checkbox"/> Crohn's Disease (CD)	<input type="checkbox"/> Ulcerative Colitis (UC)	<input type="checkbox"/> (Other) _____
---	--	--

Please answer all the following clinical questions

Is the patient's disease moderate to severe? YES NO

Did the patient have a tuberculin skin test or Centers for Disease Control (CDC) recommended equivalent to evaluate for latent tuberculosis prior to initiating vedolizumab? YES NO

Will the patient be receiving a TNF antagonist (e.g. Humira, Simponi) with Entyvio? YES NO

Will the patient be receiving Tysabri along with Entyvio? YES NO

Does the patient have any active severe infections including but not limited to: sepsis, tuberculosis, cytomegaloviral colitis, giardiasis, listeria meningitis etc.? YES NO

Does the patient have any new or worsening neurological signs or symptoms of John Cunningham virus (JCV) infection or risk of progressive multifocal leukoencephalopathy (PML)? YES NO

New Start

Continuation of Therapy

Date of last infusion: _____

Has the member demonstrated disease stability or a beneficial response to therapy? YES NO

Please attach all pertinent clinical information

Attached: YES NO

****Please verify member's eligibility and benefits through the health plan****

The following entities, which serve the noted regions, are independent licensees of the Blue Cross Blue Shield Association: Western and Northeastern PA: Highmark Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Choice Company, Highmark Health Insurance Company, Highmark Coverage Advantage Inc., Highmark Benefits Group Inc., First Priority Health, First Priority Life or Highmark Senior Health Company. Central and Southeastern PA: Highmark Inc. d/b/a Highmark Blue Shield, Highmark Benefits Group Inc., Highmark Health Insurance Company, Highmark Choice Company or Highmark Senior Health Company. Delaware: Highmark BCBSD Inc. d/b/a Highmark Blue Cross Blue Shield. West Virginia: Highmark West Virginia Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Health Insurance Company or Highmark Senior Solutions Company. Western NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Cross Blue Shield. Northeastern NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Shield.

All references to "Highmark" in this document are references to the Highmark company that is providing the member's health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.